Table 3 Univariate analysis of post-transplantation outcomes for all patients.
Variable | Outcome | 3-year probability [95% CI] | P value | |
|---|---|---|---|---|
Region | Europe | Asia | ||
PFS | 50.1% [39.2–60] | 44.4% [28–59.6] | 0.56 | |
OS | 57.7% [46.8–67.1] | 50.7% [33.4–65.6] | 0.55 | |
RI | 33.4% [23.7–43.3] | 36.1% [20.7–51.7] | 0.71 | |
NRM | 16.5% [9.7–24.9] | 19.4% [8.4–33.9] | 0.71 | |
PINK score at diagnosis | Low/intermediate | High | ||
PFS | 61.4% [41.1–76.5] | 50.9% [37.2–63] | 0.51 | |
OS | 68.4% [47.9–82.2] | 55.4% [41.2–67.5] | 0.44 | |
RI | 35.1% [18.1–52.7] | 31.6% [19.9–44] | 0.60 | |
NRM | 3.4% [0.2–15.2] | 17.5% [8.9–28.5] | 0.07 | |
Asparaginase before allo-HSCT | No | Yes | ||
PFS | 65.6% [47.4–78.9] | 42.2% [31.8–52.2] | 0.03 | |
OS | 64.8% [46.4–78.3] | 52.2% [41.4–61.9] | 0.11 | |
RI | 17.1% [6.8–31.3] | 40.4% [30.1–50.5] | 0.02 | |
NRM | 17.3% [6.9–31.7] | 17.4% [10.4–25.9] | 1.00 | |
PD–1/PD–L1 inhibitor before allo-HSCT | No | Yes | ||
PFS | 46.8% [36.5–56.4] | 53.8% [24.8–76] | 0.66 | |
OS | 53.4% [42.9–62.9] | 65.9% [31.5–86] | 0.64 | |
RI | 35.4% [25.9–45] | 23.1% [4.9–48.9] | 0.32 | |
NRM | 17.8% [10.9–26.2] | 23.1% [5.1–48.5] | 0.57 | |
Conditioning intensity | RIC | MAC | ||
PFS | 47.8% [34.6–59.8] | 49.3% [36.6–60.7] | 0.98 | |
OS | 54.3% [40.8–66] | 56.9% [44.1–67.8] | 0.92 | |
RI | 39.2% [26.7–51.4] | 29.3% [18.7–40.7] | 0.29 | |
NRM | 13.1% [6–22.9] | 21.4% [12.4–32.1] | 0.19 | |
Donor type | MRD/Unrelated | Haploidentical | ||
PFS | 50.5% [40.2–59.8] | 39% [20.2–57.4] | 0.45 | |
OS | 55.8% [45.4–64.9] | 52.6% [31.5–70] | 0.71 | |
RI | 32.6% [23.6–42] | 40.7% [21–59.6] | 0.61 | |
NRM | 16.9% [10.3–24.9 | 20.3% [7.1–38.3] | 0.67 | |
Disease status at allo-HSCT | CR/PR | Non-CR/PR | ||
PFS | 52.1% [41.6–61.6] | 37.0% [19.6–54.6] | 0.08 | |
OS | 60.6% [50.3–69.4] | 38.8% [20.4–56.9] | 0.06 | |
RI | 29.7% [20.8–39] | 51.9% [31.2–69] | 0.02 | |
NRM | 18.3% [11.3–26.5] | 11.1% [2.7–26.4] | 0.40 | |
